Published in Breast Cancer Res on March 09, 2009
GOBO: gene expression-based outcome for breast cancer online. PLoS One (2011) 2.81
Molecular characterization of basal-like and non-basal-like triple-negative breast cancer. Oncologist (2013) 2.55
A clinically relevant gene signature in triple negative and basal-like breast cancer. Breast Cancer Res (2011) 2.26
Tumor-infiltrating lymphocytes predict response to anthracycline-based chemotherapy in estrogen receptor-negative breast cancer. Breast Cancer Res (2011) 2.25
CD4⁺ follicular helper T cell infiltration predicts breast cancer survival. J Clin Invest (2013) 2.18
A signature of immune function genes associated with recurrence-free survival in breast cancer patients. Breast Cancer Res Treat (2011) 1.99
Challenges translating breast cancer gene signatures into the clinic. Nat Rev Clin Oncol (2011) 1.86
Breast cancer - one term, many entities? J Clin Invest (2011) 1.72
Building prognostic models for breast cancer patients using clinical variables and hundreds of gene expression signatures. BMC Med Genomics (2011) 1.67
Prognostic and predictive value of PDL1 expression in breast cancer. Oncotarget (2015) 1.62
Elevation of receptor tyrosine kinase EphA2 mediates resistance to trastuzumab therapy. Cancer Res (2009) 1.44
Basal breast cancer: a complex and deadly molecular subtype. Curr Mol Med (2012) 1.43
Biomarkers in Breast Cancer - An Update. Geburtshilfe Frauenheilkd (2012) 1.41
Characterization of the immunophenotypes and antigenomes of colorectal cancers reveals distinct tumor escape mechanisms and novel targets for immunotherapy. Genome Biol (2015) 1.35
Prospective validation of immunological infiltrate for prediction of response to neoadjuvant chemotherapy in HER2-negative breast cancer--a substudy of the neoadjuvant GeparQuinto trial. PLoS One (2013) 1.34
Tumour-infiltrating FOXP3(+) lymphocytes are associated with cytotoxic immune responses and good clinical outcome in oestrogen receptor-negative breast cancer. Br J Cancer (2012) 1.33
Interactions between immunity, proliferation and molecular subtype in breast cancer prognosis. Genome Biol (2013) 1.26
Kinome expression profiling and prognosis of basal breast cancers. Mol Cancer (2011) 1.22
Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. Nat Rev Clin Oncol (2016) 1.18
An integrated genomics approach identifies drivers of proliferation in luminal-subtype human breast cancer. Nat Genet (2014) 1.16
A pharmacogenomic method for individualized prediction of drug sensitivity. Mol Syst Biol (2011) 1.15
Prognostic B-cell signatures using mRNA-seq in patients with subtype-specific breast and ovarian cancer. Clin Cancer Res (2014) 1.09
A gene signature for predicting outcome in patients with basal-like breast cancer. Sci Rep (2012) 1.06
PDL1 expression in inflammatory breast cancer is frequent and predicts for the pathological response to chemotherapy. Oncotarget (2015) 1.04
Impact of CD68/(CD3+CD20) ratio at the invasive front of primary tumors on distant metastasis development in breast cancer. PLoS One (2012) 1.03
Homogeneous datasets of triple negative breast cancers enable the identification of novel prognostic and predictive signatures. PLoS One (2011) 1.03
Gene expression, molecular class changes, and pathway analysis after neoadjuvant systemic therapy for breast cancer. Clin Cancer Res (2012) 1.00
Mapping spatial heterogeneity in the tumor microenvironment: a new era for digital pathology. Lab Invest (2015) 0.98
Breast cancer patients' clinical outcome measures are associated with Src kinase family member expression. Br J Cancer (2010) 0.98
Gene-expression molecular subtyping of triple-negative breast cancer tumours: importance of immune response. Breast Cancer Res (2015) 0.98
Claudin-low breast cancers: clinical, pathological, molecular and prognostic characterization. Mol Cancer (2014) 0.96
Predicting response and survival in chemotherapy-treated triple-negative breast cancer. Br J Cancer (2014) 0.92
Genomic Analysis of Immune Cell Infiltrates Across 11 Tumor Types. J Natl Cancer Inst (2016) 0.91
Clinical-pathologic significance of cancer stem cell marker expression in familial breast cancers. Breast Cancer Res Treat (2013) 0.91
Predicting prognosis of breast cancer with gene signatures: are we lost in a sea of data? Genome Med (2010) 0.89
miR-30e* is an independent subtype-specific prognostic marker in breast cancer. Br J Cancer (2015) 0.89
A whole-genome sequence and transcriptome perspective on HER2-positive breast cancers. Nat Commun (2016) 0.88
Patient-tailored modulation of the immune system may revolutionize future lung cancer treatment. BMC Cancer (2012) 0.88
Immunoglobulin kappa C predicts overall survival in node-negative breast cancer. PLoS One (2012) 0.87
Stromal genes add prognostic information to proliferation and histoclinical markers: a basis for the next generation of breast cancer gene signatures. PLoS One (2012) 0.87
The hypoxia-inducible factor-responsive proteins semaphorin 4D and vascular endothelial growth factor promote tumor growth and angiogenesis in oral squamous cell carcinoma. Exp Cell Res (2012) 0.86
Lack of sufficiently strong informative features limits the potential of gene expression analysis as predictive tool for many clinical classification problems. BMC Bioinformatics (2011) 0.86
Distinctive responsiveness to stromal signaling accompanies histologic grade programming of cancer cells. PLoS One (2011) 0.85
Spatial organization of dendritic cells within tumor draining lymph nodes impacts clinical outcome in breast cancer patients. J Transl Med (2013) 0.85
Immune approaches to the treatment of breast cancer, around the corner? Breast Cancer Res (2014) 0.85
Systematic assessment of prognostic gene signatures for breast cancer shows distinct influence of time and ER status. BMC Cancer (2014) 0.85
Profiling the immune stromal interface in breast cancer and its potential for clinical impact. Breast Care (Basel) (2012) 0.85
A role for T-lymphocytes in human breast cancer and in canine mammary tumors. Biomed Res Int (2014) 0.85
Overview of diagnostic/targeted treatment combinations in personalized medicine for breast cancer patients. Pharmgenomics Pers Med (2013) 0.83
CD8(+) T lymphocytes infiltrating breast cancer: A promising new prognostic marker? Oncoimmunology (2012) 0.83
Lymphocyte Invasion in IC10/Basal-Like Breast Tumors Is Associated with Wild-Type TP53. Mol Cancer Res (2014) 0.83
Dual roles for immune metagenes in breast cancer prognosis and therapy prediction. Genome Med (2014) 0.82
Modelling the spatial heterogeneity and molecular correlates of lymphocytic infiltration in triple-negative breast cancer. J R Soc Interface (2015) 0.82
Hematopoietic cell kinase (HCK) as a therapeutic target in immune and cancer cells. Oncotarget (2015) 0.82
Molecular portrait of breast cancer in China reveals comprehensive transcriptomic likeness to Caucasian breast cancer and low prevalence of luminal A subtype. Cancer Med (2015) 0.81
Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy. J Immunother Cancer (2017) 0.80
Gene Expression Meta-Analysis Identifies Cytokine Pathways and 5q Aberrations Involved in Metastasis of ERBB2 Amplified and Basal Breast Cancer. Cancer Inform (2013) 0.80
Expression profiling of nuclear receptors in breast cancer identifies TLX as a mediator of growth and invasion in triple-negative breast cancer. Oncotarget (2015) 0.80
CD8+T cell-specific induction of NKG2D receptor by doxorubicin plus interleukin-12 and its contribution to CD8+T cell accumulation in tumors. Mol Cancer (2014) 0.79
Signatures of tumor-immune interactions as biomarkers for breast cancer prognosis. Future Oncol (2012) 0.79
Molecular and clinical characterization of PD-L1 expression at transcriptional level via 976 samples of brain glioma. Oncoimmunology (2016) 0.79
Preliminary characterization of IL32 in basal-like/triple negative compared to other types of breast cell lines and tissues. BMC Res Notes (2014) 0.78
Systems biology approach to studying proliferation-dependent prognostic subnetworks in breast cancer. Sci Rep (2015) 0.78
Intratumoral CD8⁺ cytotoxic lymphocyte is a favorable prognostic marker in node-negative breast cancer. PLoS One (2014) 0.78
Adaptive immunity programmes in breast cancer. Immunology (2016) 0.77
Whole-transcriptome analysis links trastuzumab sensitivity of breast tumors to both HER2 dependence and immune cell infiltration. Oncotarget (2015) 0.77
Enumerating the gene sets in breast cancer, a "direct" alternative to hierarchical clustering. BMC Genomics (2010) 0.77
Combining functional genomics strategies identifies modular heterogeneity of breast cancer intrinsic subtypes. BioData Min (2014) 0.77
Serum soluble CD14 is a potential prognostic indicator of recurrence of human breast invasive ductal carcinoma with Her2-enriched subtype. PLoS One (2013) 0.77
Immunogenic Subtypes of Breast Cancer Delineated by Gene Classifiers of Immune Responsiveness. Cancer Immunol Res (2016) 0.76
Prognostic value of PDL1 expression in pancreatic cancer. Oncotarget (2016) 0.76
Conservation of immune gene signatures in solid tumors and prognostic implications. BMC Cancer (2016) 0.75
Identification and evaluation of network modules for the prognosis of basal-like breast cancer. Oncotarget (2015) 0.75
Profile of differentially expressed intratumoral cytokines to predict the immune-polarizing side effects of tamoxifen in breast cancer treatment. Am J Cancer Res (2015) 0.75
Immune DNA signature of T-cell infiltration in breast tumor exomes. Sci Rep (2016) 0.75
Transcriptional Network Architecture of Breast Cancer Molecular Subtypes. Front Physiol (2016) 0.75
Cellular Immune Responses and Immune Escape Mechanisms in Breast Cancer: Determinants of Immunotherapy. Breast Care (Basel) (2016) 0.75
The Role of Proliferation in Determining Response to Neoadjuvant Chemotherapy in Breast Cancer: A Gene Expression-Based Meta-Analysis. Clin Cancer Res (2016) 0.75
Tumor Infiltrating Lymphocytes - The Next Step in Assessing Outcome and Response to Treatment in Patients with Breast Cancer. J Carcinog Mutagen (2014) 0.75
PDL1 expression is a poor-prognosis factor in soft-tissue sarcomas. Oncoimmunology (2017) 0.75
Prognostic and functional role of subtype-specific tumor-stroma interaction in breast cancer. Mol Oncol (2017) 0.75
Prognostic significance of interferon regulating factor 4 (IRF4) in node-negative breast cancer. J Cancer Res Clin Oncol (2017) 0.75
Immunotherapy in Breast Cancer: the Emerging Role of PD-1 and PD-L1. Curr Oncol Rep (2017) 0.75
Data-driven analysis of immune infiltrate in a large cohort of breast cancer and its association with disease progression, ER activity, and genomic complexity. Oncotarget (2017) 0.75
Impact of the Tumor Microenvironment on Tumor-Infiltrating Lymphocytes: Focus on Breast Cancer. Breast Cancer (Auckl) (2017) 0.75
Bioconductor: open software development for computational biology and bioinformatics. Genome Biol (2004) 143.19
Molecular portraits of human breast tumours. Nature (2000) 94.14
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A (2001) 71.82
Inflammation and cancer. Nature (2002) 53.78
A gene atlas of the mouse and human protein-encoding transcriptomes. Proc Natl Acad Sci U S A (2004) 44.81
[''R"--project for statistical computing]. Ugeskr Laeger (2008) 41.69
affy--analysis of Affymetrix GeneChip data at the probe level. Bioinformatics (2004) 32.08
Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet (2005) 29.45
Genes that mediate breast cancer metastasis to lung. Nature (2005) 19.85
Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst (2006) 14.60
Distinctive gene expression patterns in human mammary epithelial cells and breast cancers. Proc Natl Acad Sci U S A (1999) 14.16
Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med (2007) 13.90
An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc Natl Acad Sci U S A (2005) 13.54
Concordance among gene-expression-based predictors for breast cancer. N Engl J Med (2006) 13.50
Stromal gene expression predicts clinical outcome in breast cancer. Nat Med (2008) 10.68
Paradoxical roles of the immune system during cancer development. Nat Rev Cancer (2006) 10.57
Pitfalls in the use of DNA microarray data for diagnostic and prognostic classification. J Natl Cancer Inst (2003) 9.68
Gene expression profiling spares early breast cancer patients from adjuvant therapy: derived and validated in two population-based cohorts. Breast Cancer Res (2005) 8.73
Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade. J Clin Oncol (2007) 8.65
Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series. Clin Cancer Res (2007) 8.41
Intracellular pattern recognition receptors in the host response. Nature (2006) 8.04
Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer. J Clin Oncol (2006) 7.24
Gene expression predictors of breast cancer outcomes. Lancet (2003) 6.99
Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures. Breast Cancer Res (2008) 6.63
Macrophages regulate the angiogenic switch in a mouse model of breast cancer. Cancer Res (2006) 6.52
The humoral immune system has a key prognostic impact in node-negative breast cancer. Cancer Res (2008) 5.69
Gene expression profiling of breast cell lines identifies potential new basal markers. Oncogene (2006) 4.85
Cytokines in cancer pathogenesis and cancer therapy. Nat Rev Cancer (2004) 4.43
An immune response gene expression module identifies a good prognosis subtype in estrogen receptor negative breast cancer. Genome Biol (2007) 4.33
Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. J Exp Med (2005) 4.32
The Th1/Th2 paradigm. Immunol Today (1997) 3.96
Lung metastasis genes couple breast tumor size and metastatic spread. Proc Natl Acad Sci U S A (2007) 3.92
Identification of high risk breast-cancer patients by gene expression profiling. Lancet (2002) 2.67
Gene expression profiling shows medullary breast cancer is a subgroup of basal breast cancers. Cancer Res (2006) 2.52
High expression of lymphocyte-associated genes in node-negative HER2+ breast cancers correlates with lower recurrence rates. Cancer Res (2007) 2.48
Profile of immune cells in axillary lymph nodes predicts disease-free survival in breast cancer. PLoS Med (2005) 2.12
Naturally occurring B-cell responses to breast cancer. Cancer Immunol Immunother (2003) 1.88
Predictors of recurrence in stage I (T1N0M0) breast carcinoma. Ann Surg (1981) 1.60
Pathobiologic identification of two distinct breast carcinoma subsets with diverging clinical behaviors. Breast Cancer Res Treat (1999) 1.54
Inflammation and cancer: a double-edged sword. Cancer Cell (2007) 1.52
Effects of infiltrating lymphocytes and estrogen receptor on gene expression and prognosis in breast cancer. Breast Cancer Res Treat (2008) 1.42
Lymphoid infiltration as a prognostic variable for early-onset breast carcinomas. Clin Cancer Res (1997) 1.29
Phenotypic analysis of tumor-infiltrating lymphocytes from human breast cancer. Anticancer Res (1992) 1.19
A single-gene biomarker identifies breast cancers associated with immature cell type and short duration of prior breastfeeding. Endocr Relat Cancer (2005) 1.18
Correlation of KIT and EGFR overexpression with invasive ductal breast carcinoma of the solid-tubular subtype, nuclear grade 3, and mesenchymal or myoepithelial differentiation. Cancer Sci (2005) 1.11
Poor outcome in estrogen receptor-positive breast cancers predicted by loss of plexin B1. Clin Cancer Res (2007) 1.07
A better way for a cancer cell to die. N Engl J Med (2006) 1.05
In situ quantitation of inflammatory mononuclear cells in ductal infiltrating breast carcinoma. Relation to prognostic parameters. Am J Pathol (1987) 1.03
Antibody response against the c-erbB-2 oncoprotein in breast carcinoma patients. Cancer Res (1993) 1.02
Loss of Plexin B1 is highly prognostic in low proliferating ER positive breast cancers--results of a large scale microarray analysis. Eur J Cancer (2008) 0.96
Characterization of T-lymphocyte subpopulations infiltrating primary breast cancer. Cancer Immunol Immunother (1989) 0.93
Preoperative (neoadjuvant) systemic treatment of breast cancer. Breast (2005) 0.89
Immune cells as anti-cancer therapeutic targets and tools. J Cell Biochem (2007) 0.89
Functional analysis of tumor-infiltrating leukocytes in breast cancer patients. J Surg Res (1998) 0.88
Frequent KIT and epidermal growth factor receptor overexpressions in undifferentiated-type breast carcinomas with 'stem-cell-like' features. Cancer Sci (2005) 0.88
Breast cancer and the immune system: opportunities and pitfalls. J Mammary Gland Biol Neoplasia (2001) 0.83
"Stem cell like" breast cancers-a model for the identification of new prognostic/predictive markers in endocrine responsive breast cancer exemplified by Plexin B1. Eur J Obstet Gynecol Reprod Biol (2008) 0.78
Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. J Clin Oncol (2009) 10.18
2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet (2007) 9.24
Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol (2012) 8.74
Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol (2009) 7.21
Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study. J Clin Oncol (2009) 6.56
Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J Clin Oncol (2009) 6.51
Genomewide comparison of DNA sequences between humans and chimpanzees. Am J Hum Genet (2002) 5.80
From latent disseminated cells to overt metastasis: genetic analysis of systemic breast cancer progression. Proc Natl Acad Sci U S A (2003) 4.79
Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer. N Engl J Med (2012) 4.24
Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study. Lancet Oncol (2013) 3.92
Response-guided neoadjuvant chemotherapy for breast cancer. J Clin Oncol (2013) 3.29
A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors. Clin Cancer Res (2011) 2.79
Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial. Lancet Oncol (2012) 2.72
Identification of high risk breast-cancer patients by gene expression profiling. Lancet (2002) 2.67
Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study. J Clin Oncol (2010) 2.54
Molecular characterization of breast cancer with high-resolution oligonucleotide comparative genomic hybridization array. Clin Cancer Res (2009) 2.49
Treatment of breast cancer during pregnancy: an observational study. Lancet Oncol (2012) 2.38
Neoadjuvant vinorelbine-capecitabine versus docetaxel-doxorubicin-cyclophosphamide in early nonresponsive breast cancer: phase III randomized GeparTrio trial. J Natl Cancer Inst (2008) 2.35
A clinically relevant gene signature in triple negative and basal-like breast cancer. Breast Cancer Res (2011) 2.26
Effect of RNA silencing of polo-like kinase-1 (PLK1) on apoptosis and spindle formation in human cancer cells. J Natl Cancer Inst (2002) 2.25
Intensified neoadjuvant chemotherapy in early-responding breast cancer: phase III randomized GeparTrio study. J Natl Cancer Inst (2008) 2.20
Biological impact of freezing Plk1 in its inactive conformation in cancer cells. Cell Cycle (2010) 2.18
Breast carcinoma during pregnancy. International recommendations from an expert meeting. Cancer (2006) 2.04
Microarray analysis of altered sphingolipid metabolism reveals prognostic significance of sphingosine kinase 1 in breast cancer. Breast Cancer Res Treat (2007) 2.01
Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the GEPARDUO study of the German Breast Group. J Clin Oncol (2005) 1.99
Recommendations from an international consensus conference on the current status and future of neoadjuvant systemic therapy in primary breast cancer. Ann Surg Oncol (2011) 1.83
A comprehensive analysis of human gene expression profiles identifies stromal immunoglobulin κ C as a compatible prognostic marker in human solid tumors. Clin Cancer Res (2012) 1.83
Brief report: tracheal intubation using the Bonfils intubation fibrescope or direct laryngoscopy for patients with a simulated difficult airway. Can J Anaesth (2008) 1.82
Randomized phase III trial of pegylated liposomal doxorubicin versus vinorelbine or mitomycin C plus vinblastine in women with taxane-refractory advanced breast cancer. J Clin Oncol (2004) 1.82
Long-term downregulation of Polo-like kinase 1 increases the cyclin-dependent kinase inhibitor p21(WAF1/CIP1). Cell Cycle (2009) 1.75
Adjuvant lapatinib for women with early-stage HER2-positive breast cancer: a randomised, controlled, phase 3 trial. Lancet Oncol (2012) 1.75
BRAF mutations in colorectal carcinoma suggest two entities of microsatellite-unstable tumors. Cancer (2005) 1.75
Origin and pathogenesis of nodular lymphocyte-predominant Hodgkin lymphoma as revealed by global gene expression analysis. J Exp Med (2008) 1.74
Impact of treatment characteristics on response of different breast cancer phenotypes: pooled analysis of the German neo-adjuvant chemotherapy trials. Breast Cancer Res Treat (2010) 1.60
HMGB1 inhibits cell death in yeast and mammalian cells and is abundantly expressed in human breast carcinoma. FASEB J (2003) 1.59
Cyclin B1 depletion inhibits proliferation and induces apoptosis in human tumor cells. Oncogene (2004) 1.55
Gene expression profiling of luminal B breast cancers reveals NHERF1 as a new marker of endocrine resistance. Breast Cancer Res Treat (2011) 1.53
Downregulation of human polo-like kinase activity by antisense oligonucleotides induces growth inhibition in cancer cells. Oncogene (2002) 1.48
Cooperative phosphorylation including the activity of polo-like kinase 1 regulates the subcellular localization of cyclin B1. Oncogene (2002) 1.48
Effect of humidified and heated CO2 during gynecologic laparoscopic surgery on analgesic requirements and postoperative pain. J Am Assoc Gynecol Laparosc (2004) 1.48
HER2 expression and efficacy of preoperative paclitaxel/FAC chemotherapy in breast cancer. Breast Cancer Res Treat (2007) 1.47
Global gene expression profiling of formalin-fixed paraffin-embedded tumor samples: a comparison to snap-frozen material using oligonucleotide microarrays. Virchows Arch (2007) 1.45
Effectiveness of switching from adjuvant tamoxifen to anastrozole in postmenopausal women with hormone-sensitive early-stage breast cancer: a meta-analysis. Lancet Oncol (2006) 1.44
Data-driven derivation of cutoffs from a pool of 3,030 Affymetrix arrays to stratify distinct clinical types of breast cancer. Breast Cancer Res Treat (2009) 1.38
Capecitabine in addition to anthracycline- and taxane-based neoadjuvant treatment in patients with primary breast cancer: phase III GeparQuattro study. J Clin Oncol (2010) 1.33
Clinical response after two cycles compared to HER2, Ki-67, p53, and bcl-2 in independently predicting a pathological complete response after preoperative chemotherapy in patients with operable carcinoma of the breast. Breast Cancer Res (2008) 1.31
Silencing of the HER2/neu gene by siRNA inhibits proliferation and induces apoptosis in HER2/neu-overexpressing breast cancer cells. Neoplasia (2005) 1.31
Cancer inhibition in nude mice after systemic application of U6 promoter-driven short hairpin RNAs against PLK1. J Natl Cancer Inst (2004) 1.29
Capecitabine monotherapy: review of studies in first-line HER-2-negative metastatic breast cancer. Oncologist (2012) 1.29
Disseminated tumor cells in the bone marrow of patients with ductal carcinoma in situ. Int J Cancer (2011) 1.27
Borderline tumours of the ovary: A cohort study of the Arbeitsgmeinschaft Gynäkologische Onkologie (AGO) Study Group. Eur J Cancer (2013) 1.26
Nuclear export is essential for the tumor-promoting activity of survivin. FASEB J (2006) 1.25
The role of genetic breast cancer susceptibility variants as prognostic factors. Hum Mol Genet (2012) 1.23
The role of biogeography in shaping diversity of the intestinal microbiota in house mice. Mol Ecol (2013) 1.21
PTTG mRNA expression in primary breast cancer: a prognostic marker for lymph node invasion and tumor recurrence. Breast (2004) 1.21
Simultaneous statistical multiple alignment and phylogeny reconstruction. Syst Biol (2005) 1.21
Phase III trial of sunitinib in combination with capecitabine versus capecitabine monotherapy for the treatment of patients with pretreated metastatic breast cancer. J Clin Oncol (2013) 1.20
SATB1 gene expression and breast cancer prognosis. Breast (2010) 1.18
Melanoma antigen family A identified by the bimodality index defines a subset of triple negative breast cancers as candidates for immune response augmentation. Eur J Cancer (2011) 1.16